📢 Breaking News!

We're thrilled to announce that Forepont Capital Partners, a venture capital fund based in New York, specializing in investments in innovative healthcare companies has invested in Exeliom Biosciences to accelerate our clinical development in the field of immunotherapy.

Thank you Frederic Batoua, Louis Moulin and Eric M. Attias for the support and vote of confidence!

This investment by Forepont brings Exeliom's Series A funding to a total of €25 million, reinforcing our focus on three therapeutic areas: oncology, chronic inflammatory bowel diseases and infectious diseases.

Dr. Ismail Kola, Forepont’s Scientific Director, joins Exeliom’s board, bringing with him his invaluable experience in immuno-oncology. Dr. Kola’s appointment to the board underscores Forepont’s commitment to advancing Exeliom’s clinical trials and exploring the therapeutic potential of Faecalibacterium prausnitzii in cancer and immunological diseases.